Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy: A case report

Table 3 Summary of outcomes of reported studies

Ref.	PLA2R	Type of amyloidosis	Affected organs	Diagnosis of amyloidosis	Treatment	Renal outcomes
Kuroda et al[9], 2012	NA	Reactive AA (related to RA)	Renal	Renal biopsy	NSAIDs+DMARD	NA
Lu et al[10], 2017	Positive	Nonhereditary ApoA-1	Renal	Biopsy of abdominal fat, rectal mucosa, bone marrow and renal	GC+cyclosporine	Remission
Li et al[11], 2020, Patient 4	Positive	ALECT2	Renal	Renal biopsy, MS	Support therapy	Maintenance
Li et al[11], 2020, Patient 5	Suspicious Positive	ALECT2	Renal	Renal biopsy, MS	Support therapy	Maintenance
Li et al[11], 2020, Patient 6	Positive	ALECT2	Renal	Renal biopsy, MS	GC+CTX	Remission
Li et al[11], 2020, Patient 7	Suspicious Positive	ALECT2	Renal	Renal biopsy, MS	Chelation therapy (due to mercury poisoning)	Maintenance
Morel et al[12], 2022	Negative	Secondary AL (related to WM)	Retro-peritoneal, mesent-eric adipose tissue, bone marrow, bladder, cardiac and renal	Biopsy of retro-peritoneal, mesenteric adipose tissue, bone marrow, bladder, cardiac and renal	ASCT+RTX	Complete remission (after 2 yr)
Wang et al[13], 2022	Positive	Primary AL	Renal	Renal biopsy	Support therapy	NA
The present case	Positive	Primary AL	Renal	Renal biopsy	RTX+GC+CyBorD	Complete remission (after 21 mo)

AA: Amyloid A; ApoA-1: Apolipoprotein A-1; ALECT2: Leukocyte chemotactic factor 2; AL: Amyloid light chain; ASCT: Autologous stem cell transplantation; CTX: Cyclophosphamide; CyBorD: Cyclophosphamide, bortezomib, and dexamethasone; DMARD: Disease-modifying antirheumatic drug; GC: Glucocorticoid; MS: mass spectrometry; NA: Not available; Negative: Negativetive; NSAIDs: Non-steroidal anti-inflammatory drugs; PLA2R: Phospholipase A2 receptor; Positive: Positivetive; RA: Rheumatoid arthritis; RTX: Rituximab; WM: Waldenström macroglobulinemia.